Drug Profile

IMA 001

Alternative Names: IMA-001

Latest Information Update: 25 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Imalia
Developer Imalia; Nuvamid
Class Antianaemics; Nucleotides; Small molecules
Mechanism of Action Antioxidants; Sickle haemoglobin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Clinical Phase Unknown Sickle cell anaemia

Most Recent Events

25 Sep 2025 Imalia announced the intention to initiate a phase II trial for Sickle cell anemia(In adolescents, In adults, In the elderly) in the US, Europe, Middle East, India(PO) in 2026 (Imalia website, September 2025)
07 Dec 2024 Imalia and Nuvamid agree to co-develop IMA 001 for Sickle cell anemia, prior to December 2024
07 Dec 2024 Preclinical trials in Sickle cell anaemia in Switzerland (Intraperitoneal)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com